1. MARKETS
  2. SECTOR : HEALTHCARE & MEDICAL EQUIPMENT SUPPLIERS
  3. INDUSTRY : MEDICAL SPECIALTIES
  4. BOSTON SCIENTIFIC CORP.
Boston Scientific Corp.
XNYS: BSX
Falling Comet
Download real time
42.730.69(1.64%)
New 52W Low in past week
12.8M
XNYS Volume

XNYS 09 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Boston Scientific quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Boston Scientific share price target, revenues, EPS, net income and more

Boston Scientific quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • POSITIVE

    Quarterly Revenue Boston Scientific Jun-2026 Quarterly Revenue is $5,442 Million which is growth of 7.5% YoY.

  • POSITIVE

    Quarterly Net Profit Boston Scientific Jun-2026 Quarterly Net Profit is $907 Million which is growth of 13.8% YoY.

Boston Scientific Corp., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
5,4425,2035,2865,0655,0614,6634,5614,2094,1203,8563,7253,5273,599
Cost Of Rev.
1,5941,5901,6081,5231,6371,4531,4661,3121,2701,2091,1471,1011,070
Gross Profit
3,8483,6133,6783,5423,4243,2103,0952,8972,8502,6472,5782,4262,529
⌄
2,6022,5412,6372,4922,4812,2732,3052,1792,0511,9541,9611,8171,923
Operating Profit
1,2461,0721,0411,050943937790718799693617609606
⌄
-96-90-61-87-90-8227-79-77-69-43-66-70
Profit Before Tax
1,0601,162700939941805585669420608505610426
Tax
155-1763018314613323200981151105156
⌄
9071,341672755797674565469324495505505261
Diluted NI Avail to Com Stockholders Ann.
9071,341672755797674565469324495505505261
Basic EPS
0.60.90.50.50.50.50.40.30.20.30.30.30.2
Diluted EPS After ExtraOrdinary
0.70.90.50.50.60.50.50.30.40.30.40.30.2
Number Of Shares End
1,470.21,484.91,482.81,481.71,479.91,477.21,474.21,472.71,470.61,468.41,465.61,464.51,446.2
Net Income Continuing Discontinued Operations
9071,341672755797674566468324492505504270
Normalized Income
965.11,324.8758.1757.4901.8686.5765.8457.5537.7508.2637.7435.4328.3
Interest Income
-------------
Interest
96909087908280797769656670
Net Interest Income
-96-90-61-87-90-8227-79-77-69-43-66-70
EBIT
1,1561,2527901,0261,031887665748497677570676496
EBITDA
1,5111,6031,1551,3681,3671,2121,0131,054808981883976794
Reconciled Cost Of Rev.
1,4721,4711,4711,4061,5261,3471,3431,2111,1721,1191,0421,009982
Reconciled Depr.
355351365342336325348306311304313300298
Profit From Continuing Operations
9041,339670755795672562469322493504504270
Normalized EBITDA
1,5791,5761,2451,3711,4911,2271,2211,0391,0871,0011,016893886
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Boston Scientific competitor comparison and performance snapshot within industry

Boston Scientific annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Annual Revenue Boston Scientific Dec-2025 Annual Revenue is $20,074 Million which is growth of 19.9% YoY.

  • POSITIVE

    Annual Net Profit Boston Scientific Dec-2025 Annual Net Profit is $2,898 Million which is growth of 56.3% YoY.

Boston Scientific Corp., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
16.5%
15.2%
 20,07416,74714,24012,68211,8889,91310,7359,8239,0488,3867,477
Cost Of Rev. Ann.
15.8%
12.1%
6,3156,2215,2574,3454,0033,7603,5103,1812,8832,6612,5032,243
Gross Profit Ann.
16.9%
16.7%
14,68113,85311,4909,8958,6798,1286,4037,5546,9406,3875,8835,234
Operating Exp. Ann.
14.1%
11.6%
10,2729,8828,4887,4786,6466,3045,7195,8145,2814,8564,5644,244
Operating Profit Ann.
25%
42.2%
4,4093,9713,0022,4172,0331,8246841,7401,6591,5311,319990
⌄
-
-
-334-320-198-243-460-337-358-443-238-224-228-279
Other Exp. Ann.
-
-
 -267-521-188-434-412-405-612-1-375-914-1,361
PBT Ann.
43.7%
-
3,8613,3852,2821,9851,1411,076-796871,422933177-650
Tax Ann.
3.6%
200.9%
192493436393443362-4,013-249828-170-411
⌄
65.3%
-
3,6752,8981,8531,570642985-1154,7001,671104347-239
Diluted NI Avail to Com Stockholders Ann.
65.3%
-
3,6752,8981,8531,570642985-1154,7001,671104347-239
EPS Ann.
58.7%
-
 21.31.10.50.7-0.13.41.20.10.3-0.2
Diluted EPS Ann.
56%
-
 1.91.31.10.50.7-0.13.31.20.10.3-0.2
Number Of Shares End
1.1%
0.8%
 1,482.81,474.21,465.61,432.91,425.31,427.81,394.21,3841,373.11,362.11,345.7
Total Exp. Ann.
14.8%
11.8%
 16,10313,74511,82310,64910,0649,2298,9958,1647,5177,0676,487
Net Income Continuing Discontinued Operations Ann.
60.7%
-
3,6752,8981,8541,5936981,041-824,7001,671104347-239
Normalized Income Ann.
48.1%
57.6%
3,805.43,096.12,2521,732.6953.41,430.7318.15,1461,661.5315.8890.6569.2
Interest Income Ann.
42.6%
57.4%
 29107221043303555
Interest Ann.
-9.4%
-0.7%
363349305265470341361473241229233284
EBITDA Ann.
22.9%
29.4%
5,6375,1023,8563,4462,7472,5101,4052,1712,5572,0061,225403
Reconciled Cost Of Rev. Ann.
16.1%
12.6%
5,8205,7504,8443,9773,6703,4083,1762,8692,5882,3822,2331,969
Reconciled Depr. Ann.
6.4%
4%
1,4131,3681,2691,1961,1361,0931,1231,011894844815769
Profit From Continuing Operations Ann.
60.6%
-
3,6682,8921,8461,5926981,041-824,7001,671104347-239
Normalized EBITDA Ann.
19%
24%
5,7715,3344,3483,6203,1652,9131,8172,7822,5442,3592,1311,750
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
19.9%
2Y CAGR
18.7%
3Y CAGR
16.5%
5Y CAGR
15.2%
7Y CAGR
10.7%
10Y CAGR
10.4%
Total Revenue Annual growth is higher than historical averages.
Net Profit Ann.
1Y CHG
56.3%
2Y CAGR
34.9%
3Y CAGR
60.7%
7Y CAGR
8.2%
Net Profit Annual growth is stable compared to historical averages.
Operating Exp. Ann.
1Y CHG
16.4%
2Y CAGR
15%
3Y CAGR
14.1%
5Y CAGR
11.6%
7Y CAGR
9.4%
10Y CAGR
8.8%
Operating Expenses Annual Cr growth is higher than historical averages.

Boston Scientific balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Boston Scientific Dec-2025 Total Shareholders Fund is $24,232 Million which is growth of 11.3% YoY.

  • POSITIVE

    Total Assets Boston Scientific Dec-2025 Total Assets is $43,673 Million which is growth of 10.9% YoY.

Boston Scientific Corp., Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
10.4%
7.3%
43,67339,39535,13632,46932,22930,77730,56520,99919,04218,09618,133
⌄
8.8%
4.4%
19,20117,39215,60614,89615,60715,45116,68812,27312,03011,36311,813
⌄
11.3%
9.6%
24,23221,77019,28117,57416,62315,32713,8778,7257,0116,7336,320
Total Capitalization Ann.
10%
7.6%
35,24430,61227,84726,48425,41824,44522,46913,49610,82612,15311,994
Tangible Assets Ann.
-
-
-1,070-2,003-1,109-1,249-1,485-540-4,185-5,558-5,824-5,828-6,347
Working Capital Ann.
19.7%
2.2%
3,3555211,5811,9572,0433,013-167-1,257-1,832-3481,041
Invested Capital Ann.
10.3%
7.8%
35,54332,39028,37826,50425,67924,45823,88515,74912,62712,21711,997
Tangible Book Value Ann.
-
-
-1,070-2,003-1,109-1,249-1,485-540-4,185-5,558-5,824-5,828-6,347
Borrowings Ann.
7.2%
3.7%
11,43611,1479,4929,2829,4519,53910,2847,0305,6165,4845,677
Net Debt Ann.
5.3%
4.8%
9,34610,2068,2328,0027,1317,3979,7916,8785,4285,2885,358
Share Issued Ann.
1%
0.8%
1,746.31,737.91,7291,696.61,688.81,679.91,642.51,632.21,621.11,609.71,594.2
Number Of Shares End
1.1%
0.8%
1,482.81,474.21,465.61,432.91,425.31,427.81,394.21,3841,373.11,362.11,345.7
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
10.9%
2Y CAGR
11.5%
3Y CAGR
10.4%
5Y CAGR
7.3%
7Y CAGR
11%
10Y CAGR
9.2%
Total Assets Annual growth is stable compared to historical averages.
Total Current Liabilities Ann.
1Y CHG
-15%
2Y CAGR
5%
3Y CAGR
12.7%
5Y CAGR
8.1%
7Y CAGR
0.5%
10Y CAGR
8.4%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
11.3%
2Y CAGR
12.1%
3Y CAGR
11.3%
5Y CAGR
9.6%
7Y CAGR
15.7%
10Y CAGR
14.4%
Total ShareHolders Funds Annual growth is stable compared to historical averages.

Boston Scientific ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share Boston Scientific Book Value Per Share is $17 which is growth of 13.7% YoY.

  • NEUTRAL

    ROE Boston Scientific ROE is 0% which is growth of 0% YoY.

Boston Scientific Corp., Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
-4.97%4.64%1.98%3.13%-0.37%18.23%8.35%0.56%1.92%-1.36%
ROE Ann. %
-
-
-9.03%8.52%3.75%6.17%-0.79%41.59%21.24%1.51%5.32%-3.74%
ROIC %
-
-
-220.70.61.118.52.8-4.51.3-0.9
OPM Ann. %
7.3%
23.4%
19.78%17.93%16.97%16.03%15.34%6.90%16.21%16.89%16.92%15.73%13.24%
Inventory Turnover Ratio Ann.
-
-
-222.32.52.42.32.62.62.52.3
Asset Turnover Ann. %
-
-
-0.50.40.40.40.30.40.50.50.50.4
Working Capital Turnover Ann.
-2.6%
12.7%
632.196.55.83.3-64.3-7.8-4.9-24.17.2
Quick Ratio Ann.
-
-
-0.50.60.80.90.90.40.30.30.50.7
Current Ratio Ann.
-
-
-1.11.31.51.51.810.80.70.91.4
Interest Coverage Ratio Ann.
-
-
-8.58.53.44.20.82.56.95.11.8-1.3
LT Debt To Equity Ann.
-
-
-0.40.50.50.60.60.60.60.50.80.9
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Boston Scientific cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Cash From Operating Activity Boston Scientific Dec-2025 Cash From Operating Activity is $4,534 Million which is growth of 32.0% YoY.

  • POSITIVE

    Net Cash Flow Boston Scientific Dec-2025 Net Cash Flow is $1,500 Million which is growth of 440.9% YoY.

Boston Scientific Corp., Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
43.7%
24.6%
4,5343,4342,5041,5271,8711,5091,8383111,425972600
⌄
-
-
-2,639-5,687-2,575-2,011-1,596-411-5,042-1,922-1,010-887-2,186
⌄
-
-
-3951,8135-547-952942,9731,431110-2061,322
Cash Plus Cash Eqv. End Of Year Ann.
24%
1.5%
2,1476061,0551,1262,1681,9956078291,017196319
Net Increase In Cash Plus Cash Eqv.s Ann.
-
1.5%
1,499-438-67-1,0331791,390-232-180526-121-264
Cash Plus Cash Eqv. Begin Of Year Ann.
-34.6%
0%
6061,0551,1262,1681,9956078291,017487319587
Income Tax Paid Supplemental Data Ann.
-5.4%
22.1%
5616565126623022072421,037-9480
Interest Paid Supplemental Data Ann.
-10.8%
-2.3%
319250259450338359449262235233283
Capex Ann.
-
-
-1,130-1,070-800-588-554-522-610-488-450-508-513
Issuance Of Capital Stock Ann.
-
-
---1,95012310185111114
Issuance Of Debt Ann.
-21.9%
-23.2%
1,5582,3563,2705,8447,9292,5763,3396303,145
Repayment Of Debt Ann.
-
-
-2,049-529-4-3,435-6,843-5,135-1,171-3,216-820-1,715
Repurchase Of Capital Stock Ann.
-
-
----535---
Free Cash Flow Ann.
53.7%
28.1%
3,4042,3651,7039381,3169861,226-17897646487
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Operating Act. Ann.
1Y CHG
32%
2Y CAGR
34.6%
3Y CAGR
43.7%
5Y CAGR
24.6%
7Y CAGR
46.6%
10Y CAGR
22.4%
Cash from Operating Activity Annual growth is stable compared to historical averages.
×